Navigation Links
Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
Date:12/22/2009

ant (p=0.34), the difference in mortality between the high-dose group and placebo was 6.7%.

The greatest benefit was observed in the population at the highest risk of mortality as assessed by APACHE II Predicted Risk of Mortality (PROM). In patients who were considered at higher risk of death, mortality among placebo patients was 56.3% versus 33.3% in high-dose patients (p=0.105).

About ACCESS

Based on the trial results, Eisai is now conducting a global Phase III clinical trial program, called ACCESS (A Controlled Comparison of Eritoran tetrasodium and Placebo in Patients with Severe Sepsis). The trial will further evaluate eritoran as a potential treatment for severe sepsis, the second most frequent cause of death in intensive care patients in the U.S., surpassed only by cardiovascular events. In the European Union (EU), sepsis is the most common cause of death in the ICU.

The ACCESS trial population will enroll substantially more patients than the Phase II trial and has been sized (n=2,000) to determine the efficacy (reduction in 28-day all-cause mortality) of eritoran and targets a population with severe sepsis that has a moderate-to-high risk of mortality as determined by baseline APACHE II (Acute Physiology and Chronic Health Evaluation II) scores from 21 to 37. APACHE II is a severity of illness scoring system commonly used in sepsis research and ICUs.

About Eritoran, TLR4 and Severe Sepsis

Sepsis is a condition involving infection and inflammation. The body's normal response to an infection is to initiate an immunological chain reaction of inflammation. In severe sepsis, systemic inflammation may be an overreaction leading to injury and failure of one or more organ systems that may become life-threatening. The toll-like receptor 4 (TLR4) is part of the innate immune system and, when it is activated, TLR4 may play an important role
'/>"/>

SOURCE Eisai
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
2. ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
3. American Imaging Managements New Specialty Drug Program Delivers Immediate Results
4. Hospira to Host Conference Call for Fourth-Quarter 2009 Results and 2010 Projections
5. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
6. Immucor to Announce Fiscal Second Quarter Financial Results on Wednesday, January 6, 2010
7. Robbins & Myers To Release First Quarter Fiscal 2010 Financial Results
8. Champions Biotechnology Reports Fiscal 2010 Second Quarter Financial Results
9. AVAC Says MDP 301 Microbicide Trial Results Disappointing, but Researchers and 9,400 Trial Volunteers Deserve Praise for Successful Trial
10. Pro-Dex, Inc. Announces Results of Annual Shareholder Meeting, an Update Regarding Major Customers Product Development Plans, and Receipt of $1.5 Million and $3.0 Million Purchase Orders
11. Neogen Corporation Announces 2nd Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... PARK, N.C. , Sept. 19, 2014 /PRNewswire/ ... on cloud-based drug design and development, partnering is ... company,s mission is to design new drugs and ... and 2 partners to further their development. The ... portfolio investments. To support this business model, Cloud ...
(Date:9/19/2014)... , Sept. 19, 2014 Research and ... Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market ... For the purposes of this report, the human microbiome ... The human microbiome market is expected to be valued ... at a CAGR of 22.3% within the forecast period of ...
(Date:9/19/2014)... Sept. 19, 2014 The American Association for ... Design and Manufacturing has joined the AAHomecare Corporate Partner ... Harvey Diamond have been actively involved in AAHomecare ... it has quickly grown into a major global manufacturer ... Drive allows AAHomecare to increase efforts on behalf of ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
... Mich., March 6 NanoBio(R) Corporation has,received its third ... having successfully met three critical development milestones:,validating the efficacy ... and demonstrating the strength of its influenza vaccine in,ferret ... of Michigan, has received a,total of $30 million over ...
... lower cardiac toxicity drives ... investigator interest, ... MTA: CTIC) announced today that its investigational drug,pixantrone will be ... Charcot Stichting, in Brussels, Belgium, which sponsors a,consortium of centers ...
Cached Medicine Technology:NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones 2Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis 2Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis 3Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis 4
(Date:9/20/2014)... New York, New York (PRWEB) September 20, 2014 ... of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in ... notes that yet another insurer has announced plans ... a statement posted on its website last month, ... such procedures effective November 1, 2014. The insurer ...
(Date:9/20/2014)... 20, 2014 The excitement is building up once ... North Carolina. This year the Surry Arts Council will be ... around the country who are still fans of the Andy Griffith ... sitcom that aired on CBS from 1960 through 1968. The ... American television history. Mount Airy, North Carolina is where the ...
(Date:9/20/2014)... September 20, 2014 Recently, UWDress.com, an ... and women’s special occasion outfits, has launched a special ... company’s prom outfits are popular among worldwide clients. Now, ... wholesale prom dresses on its website. , ... customers from around the world. Great custom made items ...
(Date:9/20/2014)... 2014 QueenBeeTickets.com is ready to offer ... performances. She will visit many cities in North America ... 16th of April. , Click Here to ... at QueenBeeTickets.com. , The star’s fans are not going ... favorite young singer in a live performance. Ariana Grande ...
(Date:9/20/2014)... 20, 2014 The Arizona Advanced ... is celebrating National Manufacturing Day by opening its doors ... processing and additive manufacturing labs will be offered between ... at MCC’s Southern and Dobson campus (1833 W. Southern ... Lot D. , The AzAMI at MCC was established ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
... , , , GAITHERSBURG, Md., ... Health and Human Services (HHS) has placed an order for an ... against the 2009 H1N1 influenza virus. This brings HHS orders ... total cumulative contract value of approximately $453 million. Previous HHS ...
... and minimally invasive techniques, study finds , MONDAY, Sept. ... is possible using either minimally invasive or traditional open ... for the type of fracture, researchers say. , The ... factors such as fracture type and degree of septal ...
... in times of uncertainty, people would gravitate toward familiar,favorites. But ... shows that stress and upheaval actually lead people to ... can name our favorite ,comfort foods, and believe that we ... stress and upheaval," writes author Stacy Wood (University of South ...
... , , Projects Target ... WASHINGTON, Sept. 21 Secretary of Veterans Affairs Eric K. Shinseki announced ... $1.4 billion as the Department,s share of spending under the American Recovery ... , , "In putting America back to work, we ...
... FRANCISCO, CA ─ SEPTEMBER 21, 2009 ... drug-eluting stents are effective with a low rate of ... 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored ... study, "The Effect of Drug-Eluting Stents on Clinical and ...
... 2009 A new type of sirolimus-eluting stent ... paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding ... SES over the PES stent for the trial,s primary ... RES-ELUTION I Trial on the safety and effectiveness of ...
Cached Medicine News:Health News:MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 2Health News:MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 3Health News:Best Option for Fractured Nose Varies by Patient 2Health News:Comfort food fallacy: Upheaval leads to less-familiar choices 2Health News:Secretary Shinseki Announces Progress on $1.4 Billion in Recovery Act Spending 2Health News:Researchers find drug-eluting stents safe, effective for PCI in diabetics 2Health News:New type of sirolimus-eluting stent demonstrates superior results 2Health News:New type of sirolimus-eluting stent demonstrates superior results 3
PremierEdge™ Stab Knives - 15°....
VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: